Amman:Jordan's pharmaceutical industry has solidified its presence in 85 global markets, leveraging its growing manufacturing and research capabilities, technical expertise, and commitment to international quality standards. This expansion has positioned the sector as a significant industrial driver for diversifying exports and supporting economic growth.
According to Qatar News Agency, the industry's exports reached approximately $905 million in 2025, demonstrating a transition from meeting domestic needs to competing internationally. Mazen Darwazeh, Executive Vice Chairman and Deputy CEO, MENA at Hikma Pharmaceuticals, highlighted the sector's global foothold, attributing success to investments in research, qualified human capital, and adherence to quality standards.
Darwazeh noted that Jordanian pharmaceutical exports continued their upward momentum in the first quarter of 2026, reflecting a 17.6 percent increase compared to the previous year. This growth underscores the external demand and competitiveness of Jordanian pharmaceuticals in regional and international markets.
Prospects for cooperation with Qatar are promising, as Jordanian medicines are present in Qatari pharmacies and hospitals. Darwazeh emphasized the potential for strategic partnerships and expertise sharing to serve mutual interests, supported by strong economic ties between the two nations.
The sector includes around 30 manufacturing facilities, generating approximately 10,000 jobs and producing a wide range of therapeutic products. The recent accession of the Jordan Food and Drug Administration to the Pharmaceutical Inspection Co-operation Scheme enhances international recognition and market confidence.
Darwazeh stressed the importance of sustained investment in research and development, technology, and international partnerships to maintain the industry's achievements and support its growth as a key pillar of Jordan's economy.